Impaired DNA repair and genomic stability in hereditary tyrosinemia type 1

被引:5
|
作者
van Dyk, E. [1 ]
Pretorius, P. J. [1 ]
机构
[1] North West Univ, Ctr Human Metabon, Sch Phys & Chem Sci, ZA-2520 Potchefstroom, South Africa
基金
新加坡国家研究基金会;
关键词
Hereditary tyrosinemia; Microsatellite instability; Gene expression; Genetic instability; Hepatocellular carcinoma; MESSENGER-RNA LEVELS; MICROSATELLITE INSTABILITY; EXCISION-REPAIR; MURINE MODEL; FUMARYLACETOACETATE; CANCER; LIVER; EXPRESSION; DAMAGE; STRESS;
D O I
10.1016/j.gene.2011.12.021
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The autosomal recessive disorder, hereditary tyrosinemia type 1 (HT1), is caused by a defective fumarylacetoacetate hydrolase enzyme. Consequently intermediate metabolites such as fumarylacetoacetate, succinylacetone and p-hydroxyphenylpyruvic acid accumulate. Characteristic to HT1 is the development of hepatocellular carcinoma, irrespective of dietary intervention or pharmacological treatment. Carcinogenesis may occur through a chromosomal instability mutator phenotype or a microsatellite instability phenotype, and deficient DNA repair may be a contributing factor thereof. The purpose of this study was to investigate the expression of DNA repair proteins, and the possible occurrence of microsatellite instability in HT1. Gene expression analyses show low expression of hOGG1 and ERCC1 in HT1 patient lymphocytes. Results from microsatellite instability analyses show allelic imbalance on chromosome 7 of the fah(-/-) mouse genome, and instability of the 025123, D5S346 and (possibly) D17S250 microsatellite markers, in HT1 patient lymphocytes. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 50 条
  • [41] Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients
    Zeybek, Ayse Cigdem Aktuglu
    Kiykim, Ertugrul
    Neselioglu, Salim
    Iscan, Halise Zeynep
    Zubarioglu, Tanyel
    Cansever, Mehmet Serif
    Erel, Ozcan
    PEDIATRIC RESEARCH, 2022, 92 (02) : 474 - 479
  • [42] Preclinical Assessment of an In Vivo Lentiviral Vector Cure for Hereditary Tyrosinemia Type 1
    Kaiser, Robert A.
    Nicolas, Clara T.
    Allen, Kari L.
    VanLith, Caitlin J.
    Du, Zeji
    Hillin, Lori G.
    Cao, William
    Bhagwate, Aditya
    O'Brien, Daniel
    Kocher, Jean-Pierre
    Hickey, Raymond D.
    Mondal, Gourish
    Lillegard, Joseph B.
    MOLECULAR THERAPY, 2020, 28 (04) : 426 - 426
  • [43] THE ENZYME DEFECTS IN HEREDITARY TYROSINEMIA TYPE-I
    FURUKAWA, N
    HAYANO, T
    SATO, N
    INOUE, F
    MACHIDA, Y
    KINUGASA, A
    IMASHUKU, S
    KUSUNOKI, T
    TAKAMATISU, T
    JOURNAL OF INHERITED METABOLIC DISEASE, 1984, 7 : 137 - 138
  • [44] Impact of nitisinone treatment and discontinuation on the metabolome of wild type and hereditary tyrosinemia type 1 mice
    Colemonts-Vroninks, Haaike
    Norman, Brendan P.
    Andrew, Davison
    Neuckermans, Jessie
    Lionel, Marcelis
    Anneleen, Mortier
    Dimitri, De Bundel
    Ranganath, Lakshminarayan
    Geert, Martens
    Vanhaecke, Tamara
    James, Gallagher
    De Kock, Joery
    JOURNAL OF HEPATOLOGY, 2020, 73 : S540 - S541
  • [45] CHROMOSOMAL INSTABILITY IN HEREDITARY TYROSINEMIA TYPE-I
    WILSON, KS
    TIMMONS, CF
    HILTON, DS
    WEINBERG, AG
    TONK, V
    PEDIATRIC PATHOLOGY, 1994, 14 (06): : 1055 - 1057
  • [46] NEONATAL SCREEN FOR HEREDITARY TYROSINEMIA TYPE-I
    HOLME, E
    LINDSTEDT, S
    LANCET, 1992, 340 (8823): : 850 - 850
  • [47] LABORATORY MONITORING OF PATIENTS WITH HEREDITARY TYROSINEMIA TYPE I
    Schultz, Matthew
    Netzel, Brian
    Singh, Rani
    Gavrilov, Dimitar
    Oglesbee, Devin
    Raymond, Kimiyo
    Rinaldo, Piero
    Tortorelli, Silvia
    Matern, Dietrich
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (03) : 324 - 325
  • [48] VISCERAL PATHOLOGY OF HEREDITARY TYROSINEMIA TYPE-I
    RUSSO, P
    OREGAN, S
    AMERICAN JOURNAL OF HUMAN GENETICS, 1990, 47 (02) : 317 - 324
  • [49] LABORATORY MONITORING OF PATIENTS WITH HEREDITARY TYROSINEMIA TYPE I
    Schultz, Matthew
    Netzel, Brian
    Singh, Rani
    Gavrilov, Dimitar
    Oglesbee, Devin
    Raymond, Kimiyo
    Rinaldo, Piero
    Tortorelli, Silvia
    Matern, Dietrich
    MOLECULAR GENETICS AND METABOLISM, 2019, 127 (03) : 298 - 299
  • [50] Current strategies for the treatment of hereditary tyrosinemia type I
    Ashorn M.
    Pitkänen S.
    Salo M.K.
    Heikinheimo M.
    Pediatric Drugs, 2006, 8 (1) : 47 - 54